Klein Lawrence Otto, CEO, reported a transaction classified as exercise at Oruka Therapeutics, Inc. involving 75000.000000 shares for an estimated $585000.00. Reported holdings after the transaction were 1000580.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.27 to $91.26, inclusive. The reporting person undertakes to provi…
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.28 to $92.27, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.31 to $92.59, inclusive.
The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.
0 other filings
0 recent txs